安罗替尼对骨肉瘤肺转移的疗效分析
Analysis of the efficacy of anlotinib on lung metastasis of osteosarcoma
张军良 1王德辉 1范晓雯 2施鑫 1周幸 1周光新1
作者信息
- 1. 210002 南京,中国人民解放军东部战区总医院骨科
- 2. 210000 江苏省,南京中医药大学金陵临床医学院
- 折叠
摘要
目的 分析安罗替尼在骨肉瘤肺转移患者的疗效.方法 对 2018 年 1 月至 2022 年 11 月,我院收治的 28 例使用安罗替尼的骨肉瘤伴肺转移的患者进行回顾分析,中位年龄 21(7～62)岁,男19 例,女 9 例.患者肺部至少一个 5 mm 结节性病灶.所有患者 3 周为一个治疗周期(服药 2 周后停药1 周),至少服药 3 个周期以上.除 5 例行安罗替尼单药治疗外,其余患者安罗替尼联合化疗、放疗、免疫治疗或手术治疗等.结果 随访时间 4～50 个月,中位随访时间 15 个月.本组 28 例,死亡 17 例,存活11 例,总生存率 42.86%;23 例(82.14%)肺部病灶有进展,5 例肺部病灶无进展.所有病例中位无进展生存期(median progression-free survival,m-PFS)为 7.17 个月,中位总生存时间(median overall survival,m-OS)15.00 个月.经分析发现,肺部病灶体积越大,合并肺外转移灶及既往使用过靶向药物的患者治疗效果越差,预后也越差,而是否联合治疗、肺部病灶出现时间、肺部病灶数量与疗效无明显相关.所有患者中,19 例(67.86%)出现 22 例次不同程度的并发症,其中 1/2 级并发症占所有并发症的 86.36%.结论 安罗替尼对骨肉瘤肺转移患者有积极疗效,可以考虑在早期联合使用.单药使用疗效证据不足.并发症一般可耐受,可以安全使用.
Abstract
Objective To analyze the efficacy of anlotinib for patients with osteosarcoma lung metastasis.Methods A retrospective analysis was performed on 28 patients with osteosarcoma admitted to our hospital from January 2018 to November 2022.All had lung metastasis and were treated with anlotinib.The median age of patients was 21 years(range:7-62 years),including 19 males and 9 females.Patients had at least one 5 mm nodular lesion in the lungs.All patients took the drug for 3 weeks as a cycle(2 weeks of drug,1 week of discontinuation),and took the drug for at least 3 cycles or more.In addition to 5 patients with anlotinib alone,anlotinib was treated in combination with chemotherapy,radiotherapy,immunotherapy or surgery.Results Follow-up lasted 4-50 months.The median follow-up time was 15 months.There were 17 deaths and 11 survivors,and the overall survival rate was 42.86%.82.14%(23/28)of patients had progression of lung lesions,and only 5 cases had no progression of lung lesions.The median progression-free survival(m-PFS)of all cases was 7.17 months and the median overall survival(m-OS)was 15.00 months.After analysis,it was found the patients who had the larger the volume of lung lesions,or extrapulmonary metastases,or previous use of targeted drug had the worse treatment effect and the worse prognosis.Combination therapy,time of occurrence of lung lesions,and the number of lung lesions were not significantly correlated with the efficacy.Among all patients,19(67.86%)patients had 22 complications of varying degrees,of which grade 1/2 complications accounted for 86.36%of all complications.Conclusions Anlotinib has a positive effect on patients with osteosarcoma lung metastases,and early combination can be considered.There is insufficient evidence for efficacy with monotherapy.Complications are generally tolerated.
关键词
骨肉瘤/肿瘤转移/治疗结果/无进展生存期/安罗替尼Key words
Osteosarcoma/Neoplasm metastasis/Treatment outcome/Progression-free survival/Anlotinib引用本文复制引用
基金项目
国家自然科学基金青年基金(81802693)
国家自然科学基金面上项目(82373153)
出版年
2024
NETL
NSTL
万方数据